1. Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):543–9.
2. Domino JS, Baek J, Meurer WJ, Garcia N, Morgenstern LB, Campbell M, et al. Emerging temporal trends in tissue plasminogen activator use: results from the BASIC project. Neurology. 2016 Nov 22;87(21):2184–91.
3. Skolarus LE, Meurer WJ, Shanmugasundaram K, Adelman EE, Scott PA, Burke JF. Marked regional variation in acute stroke treatment among medicare beneficiaries. Stroke. 2015 Jul;46(7):1890–6.
4. Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke. 2004 Feb;35(2):e27–9.
5. Rosamond WD, Gorton RA, Hinn AR, Hohenhaus SM, Morris DL. Rapid response to stroke symptoms: the delay in accessing stroke healthcare (DASH) study. Acad Emerg Med. 1998 Jan;5(1):45–51.